Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
1.310
+0.030 (2.34%)
At close: Aug 21, 2026, 4:00 PM EDT
1.322
+0.012 (0.89%)
After-hours: Aug 21, 2026, 7:59 PM EDT
Creative Medical Technology Holdings Employees
Creative Medical Technology Holdings had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$750
Profits / Employee
-$1,510,165
Market Cap
8.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| Imunon | 20 |
| Soligenix | 14 |
| Azitra | 13 |
| CNS Pharmaceuticals | 8 |
| Aprea Therapeutics | 8 |
| AEON Biopharma | 8 |
| Traws Pharma | 7 |
CELZ News
- 1 day ago - Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’ - TheFly
- 1 day ago - Creative Medical completes enrollment in ADAPT clinical trial - TheFly
- 1 day ago - Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - GlobeNewsWire
- 15 days ago - Creative Medical receives notice of allowance for new U.S. patent - TheFly
- 15 days ago - Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms - GlobeNewsWire
- 4 weeks ago - Creative Medical files to sell 5.58M shares of common stock for holders - TheFly
- 7 weeks ago - Creative Medical Technology Holdings Issues Mid-Year Update - GlobeNewsWire
- 7 weeks ago - Creative Medical announces agreements for exercise of warrants for $4.5M - TheFly